Appl. No. : 10/530,904 Filed : April 8, 2005

AMENDMENTS TO THE SPECIFICATION

Please replace the paragraphs beginning at page 27, line 12 to page 29, line 3 with the following:

In another embodiment the present invention thus relates to a compound of the formula <u>Ha</u> or a pharmaceutically acceptable salt thereof,

formula <u>Ha</u>

$$R_4$$
 R_5
 R_2
 R_1
 R_3
 R_4
 R_4
 R_5
 R_4
 R_5
 R_4
 R_4
 R_4
 R_5

wherein R¹ is selected from the group comprising alkyl, alkenyl, alkynyl, alkyloxyalkyl, alkylthioalkyl, alkyloxycarbonyl, alkanoyl, cycloalkylalkyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkoxycarbonyl, alkylcarbonyloxyalkyl, aralkyl, arylalkenyl, arylcarbonyloxyalkyl, cycloalkylcarbonyloxyalkyl, silyloxyalkyl, aralkyl, arylalkenyl, arylcarbonyl, aryloxycarbonyl, aralkoxycarbonyl, arylthioalkyl, aralkanoyl, aroyl, silyloxyalkyl, carboxyl, alkenylcarbonyl, alkynylcarbonyl, Het¹oxyalkyl, Het¹alkoxycarbonyl, Het¹oxycarbonyl, Het¹aryloxyalkyl, Het¹aryloxyalkyl, Het¹aryloxycarbonyl,

Het¹aralkoxycarbonyl, Het¹oxyalkylcarbonyl, Het¹alkyloxyalkylcarbonyl,

Het¹aryloxyalkylcarbonyloxyalkyl, Het²oxyalkyl, Het²alkyloxyalkyl, Het²oxycarbonyl,

Het²arlkoxycarbonyl, Het²aralkoxycarbonyl, Het²aryloxycarbonyl, Het²aryloxyalkyl,

Het²arylthioalkyl, Het²oxyalkylcarbonyl, Het²alkyloxyalkylcarbonyl, Het²aryloxyalkylcarbonyl,

Het²carbonyloxyalkyl, Het²alkylcarbonyloxyalkyl, Het²aralkylcarbonyloxyalkyl, CR⁶=NR⁷,

CR⁶=N(OR⁷),

with R⁶ and R⁷ being independently selected from the group comprising hydrogen, hydroxyl, alkyl, aryl, Het¹, Het¹ alkyl, Het¹ aryl, alkenyl, alkynyl, aminoalkyl, aminoaryl, alkylcarbonylamino, arylcarbonylamino, alkylthiocarbonylamino and arylthiocarbonylamino;

Appl. No. : 10/530,904 Filed : April 8, 2005

wherein R² and R³ have the same definition as indicated above; wherein R¹ R² and R³ are optionally substituted by one or more substituents independently selected from the group as indicated above, and wherein R⁴ and R⁵ are hydrogen or alkyl.

In a preferred embodiment the uscharin derivative according to the invention is a compound having the formula Ha, wherein R¹ is selected from the group comprising alkyl, alkenyl, alkynyl, alkyloxyalkyl, alkylthioalkyl, alkanoyl, cycloalkylalkyl, cycloalkylcarbonyl, cycloalkylalkanoyl, cycloalkylthioalkyl, silyloxyalkyl, aralkyl, arylalkenyl, arylcarbonyl, arylthioalkyl, aralkanoyl, aroyl, silyloxyalkyl, carboxyl, alkenylcarbonyl, alkynylcarbonyl, Het¹oxyalkyl, Het¹aryloxyalkyl, Het¹aryloxyalkyl, Het¹aryloxyalkyl, Het¹aryloxyalkyl, Het²aryloxyalkyl, Het²aryloxyalkyl, Het²aryloxyalkyl, Het²aryloxyalkyl, Het²aryloxyalkyl, Het²aryloxyalkyl, Het²arylthioalkyl, Het²oxyalkylcarbonyl, Het²alkyloxyalkylcarbonyl, Het²aryloxyalkylcarbonyl, CR6=NR7, CR6=N(OR7), with R6 and R7 being independently selected from the group comprising hydrogen, hydroxyl, alkyl, aryl, Het¹, Het¹alkyl, Het¹aryl, alkenyl, alkynyl, aminoalkyl, aminoaryl, alkylcarbonylamino, arylcarbonylamino, alkylthiocarbonylamino and arylthiocarbonylamino;wherein R² and R³ have the same definition as above indicated; wherein R¹ R² and R³ are optionally substituted by one or more substituents independently selected from the group as indicated above, and wherein R⁴ and R⁵ are hydrogen or alkyl.

In a even more preferred embodiment, the invention relates to an uscharin derivative having the formula <u>Ha</u>, wherein R¹ is selected from the group comprising alkyl, alkenyl, alkynyl, alkyloxyalkyl, cycloalkylalkyl, cycloalkylthioalkyl, silyloxyalkyl, aralkyl, arylalkenyl, arylthioalkyl, silyloxyalkyl, carboxyl, Het¹oxyalkyl, Het¹aryloxyalkyl, Het¹aryloxyalkyl, Het²aryloxyalkyl, Het²aryloxyalkyl, Het²arylthioalkyl, Het²arylthioalkyl, Optionally substituted by one or more substituents independently selected from the group indicated in above; wherein R² and R³ are hydroxyl and wherein R⁴ and R⁵ are hydrogen or alkyl.